데일리리치앤드럭키

Sister companies aim to strengthen collaborations with biotech and pharmaceutical companies across South Korea and Asia 
They offer over two decades of expertise in biosafety and quality control testing, viral vaccine development and GMP-grade clinical manufacturing for advanced therapies and biologics

Clean Cells (https://clean-cells.com/), a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, and Naobios (https://www.naobios.com/), a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, today announce their attendance at Bio Korea 2026, (https://www.biokorea.org/en/index.do) April 28-30, in Seoul, South Korea. Both companies are part of the Clean Biologics group.

Bio Korea represents a strategic step forward in the two companies’ ongoing expansion into the Asian market, building on an established global client base there and across Europe and the US. Together, Clean Cells and Naobios collaborate to offer seamless European CRO and CDMO solutions that combine GMP manufacturing and QC (quality control) for viral products, providing a complete end-to-end service offer that is rare in this market.

Clean Cells is targeting South Korea, a fast-growing hub for cell and gene therapy and vaccines. The cell and gene therapy manufacturing market in South Korea is expected to reach a projected revenue of $1.5 billion by 2030 (https://www.grandviewresearch.com/horizon/outlook/cell-and-gene-therapy-manufacturing-market/south-korea). Clean Cells’ GMP QC and analytical services support the country’s expanding biopharma sector while reducing regulatory risk for companies seeking global approval of biologics and ATMPs.

With more than 25 years of experience, Clean Cells covers the full development continuum from early R&D to the commercial GMP stage and all major biological modalities, including viral products, cell and gene therapies, vaccines, mAbs and recombinant proteins. Its capabilities span viral safety and identity testing, genetic stability, purity testing and replication-competent particle detection; with internationally recognized expertise that is EMA GMP-certified and FDA-inspected.

“South Korea is one of the most dynamic CGT and vaccine markets in Asia. We are delighted to attend Bio Korea to meet existing and future clients and strengthen our long-term commitment in the country and more widely in Asia,” said Fran